News & Events about Editas Medicine Inc.
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting ...
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients achieved normal levels of total hemoglobin and fetal hemoglobin of >40% at 5 months and maintained these ...
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed ...
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) ...
Shares of Editas Medicine, Inc. (NASDAQ:EDIT Get Rating) have received an average recommendation of Hold from the sixteen research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold...